|
||||||||||||
NY Times reports: F.D.A. Says Bayer Failed to Reveal Drug Risk Study Posted by Rob Schneider at 09/30/06 10:19 AM The New York Times is reporting that Bayer failed to tell the FDA about results from a clinical trial that revealed their drug Trasyol may have serious risks. According to a story in the Houston Chronicle: The company says it did not reveal the data at a Sept. 21 FDA meeting held to assess the safety of Trasylol "because it was preliminary in nature and raised significant questions on the study population, outcomes and methodology," according to a company statement. "This was a mistake on the company's part." The NY Times summarized: Bayer’s study was performed by a contract research organization. But Bayer did not inform the F.D.A. that the study was being done, even though that is routine practice. The revelation comes on the heels of the Institute of Medicine's long awaited evaluation of drug safety problems at the FDA. The timing bolster's calls for broad reform of our drug safety system: Senator Charles E. Grassley, Republican of Iowa and chairman of the Senate Finance Committee and a longtime critic of the F.D.A., said Bayer’s behavior proved that the agency was largely toothless. Senator Grassley, along with Senator Chris Dodd, had called for disclosure of the results from clinical trials in legislation filed a year and a half ago. Since then, the Chair, Senator Mike Enzi, and ranking member of the Senate HELP committee, Senator Ted Kennedy, have introduced their own legislation that includes disclosure of some clinical trial results. We applauded the committee leaders' legislation, while calling for strengthening of several provisions, including assuring the results of all clinical trials are disclosed to the public, doctors, and researchers. We'll see if this most recent announcement compels needed drug safety reform forward. Comments
1
Posted by Mike Shay at 11/01/06 03:07 PM
2 Posted by Darlene Morgan at 11/01/06 11:57 PM
Post a comment
|
|
|||
| ||||